Literature DB >> 25185127

Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.

Lajos Markó1, Norbert Henke1, Joon-Keun Park1, Bastian Spallek1, Fatimunnisa Qadri1, András Balogh1, Ingrid J Apel1, Katherine I Oravecz-Wilson1, Mira Choi1, Lukasz Przybyl1, Katrina J Binger1, Nadine Haase1, Nicola Wilck1, Arnd Heuser1, Verena Fokuhl1, Jürgen Ruland1, Peter C Lucas1, Linda M McAllister-Lucas1, Friedrich C Luft1, Ralf Dechend1, Dominik N Müller2.   

Abstract

Angiotensin (Ang) II is a potent mediator of both hypertension and cardiac damage; however, the mechanisms by which this occur remain unclear. B-cell lymphoma/leukemia 10 (Bcl10) is a member of the CBM signalosome, which links Ang II and nuclear factor-κB signaling. We hypothesized that Bcl10 is pivotal in the pathogenesis of Ang II-induced cardiac damage. Ang II infusion in mice lacking Bcl10 resulted in reduced cardiac fibrosis, less cellular infiltration, and improved arrhythmogenic electric remodeling, despite a similar degree of hypertension or cardiac hypertrophy. Adoptive transfer of bone marrow (BM), whereby Bcl10 knockout or wildtype BM was transferred to their opposite genotype recipients, revealed the dual importance of Bcl10 within both cardiac and immune cells. Loss of Bcl10 in cardiac cells resulted in reduced expression of genes important for the adhesion and recruitment of immune cells. In vitro experiments demonstrated that adhesion of monocytes to Ang II-treated endothelial cells also required Bcl10. Additionally, Bcl10 deficiency in macrophages reduced their intrinsic migratory ability. To address the role of BM-derived fibroblasts in the formation of cardiac fibrosis, we explored whether Bcl10 is also important for the infiltration of BM-derived (myo)fibroblasts into the heart. The transfer of green fluorescent protein positive wildtype BM into Bcl10 knockout recipient mice revealed a reduced number of noncardiac (myo)fibroblasts compared with those wildtype recipients. Our results demonstrate the significant role of Bcl10 in multiple cell types important for the generation of Ang II-induced cardiac damage and electric remodeling and may provide a new avenue for therapeutic intervention.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  Bcl10; angiotensin II; cardiac arrhythmia; fibrosis; immune system

Mesh:

Substances:

Year:  2014        PMID: 25185127      PMCID: PMC4192031          DOI: 10.1161/HYPERTENSIONAHA.114.03900

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  30 in total

1.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor.

Authors:  R Dechend; A Fiebeler; J K Park; D N Muller; J Theuer; E Mervaala; M Bieringer; D Gulba; R Dietz; F C Luft; H Haller
Journal:  Circulation       Date:  2001-07-31       Impact factor: 29.690

Review 3.  Immune mechanisms in angiotensin II-induced target-organ damage.

Authors:  Friedrich C Luft; Ralf Dechend; Dominik N Müller
Journal:  Ann Med       Date:  2012-06       Impact factor: 4.709

4.  The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

Authors:  Linda M McAllister-Lucas; Xiaohong Jin; Shufang Gu; Katy Siu; Scott McDonnell; Jürgen Ruland; Phillip C Delekta; Matthew Van Beek; Peter C Lucas
Journal:  J Biol Chem       Date:  2010-07-05       Impact factor: 5.157

5.  NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats.

Authors:  D N Muller; R Dechend; E M Mervaala; J K Park; F Schmidt; A Fiebeler; J Theuer; V Breu; D Ganten; H Haller; F C Luft
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

6.  Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy.

Authors:  Sandra B Haudek; Jizhong Cheng; Jie Du; Yanlin Wang; Jesus Hermosillo-Rodriguez; JoAnn Trial; George E Taffet; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-05-19       Impact factor: 5.000

Review 7.  Fibrosis and cardiac arrhythmias.

Authors:  Sanne de Jong; Toon A B van Veen; Harold V M van Rijen; Jacques M T de Bakker
Journal:  J Cardiovasc Pharmacol       Date:  2011-06       Impact factor: 3.105

Review 8.  Inflammation, immunity, and hypertension.

Authors:  David G Harrison; Tomasz J Guzik; Heinrich E Lob; Meena S Madhur; Paul J Marvar; Salim R Thabet; Antony Vinh; Cornelia M Weyand
Journal:  Hypertension       Date:  2010-12-13       Impact factor: 10.190

Review 9.  Origins of cardiac fibroblasts.

Authors:  Elisabeth M Zeisberg; Raghu Kalluri
Journal:  Circ Res       Date:  2010-11-26       Impact factor: 17.367

10.  Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation.

Authors:  Takuya Uehata; Hidenori Iwasaki; Alexis Vandenbon; Kazufumi Matsushita; Eduardo Hernandez-Cuellar; Kanako Kuniyoshi; Takashi Satoh; Takashi Mino; Yutaka Suzuki; Daron M Standley; Tohru Tsujimura; Hiromi Rakugi; Yoshitaka Isaka; Osamu Takeuchi; Shizuo Akira
Journal:  Cell       Date:  2013-05-23       Impact factor: 41.582

View more
  11 in total

Review 1.  Macrophage heterogeneity and renin-angiotensin system disorders.

Authors:  Mark D Wright; Katrina J Binger
Journal:  Pflugers Arch       Date:  2017-02-08       Impact factor: 3.657

2.  Linking angiotensin II to nuclear factor-κ light chain enhancer of activated B cells-induced cardiovascular damage: bad CARMAs.

Authors:  Steven D Crowley
Journal:  Hypertension       Date:  2014-09-02       Impact factor: 10.190

3.  NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.

Authors:  Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

Review 4.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  A complex role for Bcl10 in kidney injury.

Authors:  Jiafa Ren; Steven D Crowley
Journal:  Cardiovasc Res       Date:  2020-04-01       Impact factor: 13.081

6.  Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway.

Authors:  Shudong Wang; Junlian Gu; Zheng Xu; Zhiguo Zhang; Tao Bai; Jianxiang Xu; Jun Cai; Gregory Barnes; Qiu-Ju Liu; Jonathan H Freedman; Yonggang Wang; Quan Liu; Yang Zheng; Lu Cai
Journal:  J Cell Mol Med       Date:  2017-02-03       Impact factor: 5.310

7.  Zinc Prevents the Development of Diabetic Cardiomyopathy in db/db Mice.

Authors:  Shudong Wang; Bowei Wang; Yuehui Wang; Qian Tong; Quan Liu; Jian Sun; Yang Zheng; Lu Cai
Journal:  Int J Mol Sci       Date:  2017-03-07       Impact factor: 5.923

Review 8.  BCL10 - Bridging CARDs to Immune Activation.

Authors:  Torben Gehring; Thomas Seeholzer; Daniel Krappmann
Journal:  Front Immunol       Date:  2018-07-04       Impact factor: 7.561

9.  Role of Ryanodine Type 2 Receptors in Elementary Ca2+ Signaling in Arteries and Vascular Adaptive Responses.

Authors:  Mario Kaßmann; István András Szijártó; Concha F García-Prieto; Gang Fan; Johanna Schleifenbaum; Yoland-Marie Anistan; Christoph Tabeling; Yu Shi; Ferdinand le Noble; Martin Witzenrath; Yu Huang; Lajos Markó; Mark T Nelson; Maik Gollasch
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

Review 10.  Role of Circulating Fibrocytes in Cardiac Fibrosis.

Authors:  Rong-Jie Lin; Zi-Zhuo Su; Shu-Min Liang; Yu-Yang Chen; Xiao-Rong Shu; Ru-Qiong Nie; Jing-Feng Wang; Shuang-Lun Xie
Journal:  Chin Med J (Engl)       Date:  2016-02-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.